Vowst NDC 71881-400

NDC codes

FDA NDC Directory

Product NDC (as listed)71881-400Labeler and product segments. Claims need a package NDC.

Product NDC at billing width71881-0400Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
71881-400-12	71881040012	1 BOTTLE in 1 CARTON (71881-400-12) / 12 CAPSULE in 1 BOTTLEMarketed from Apr 26, 2023

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Vowst
Generic name (nonproprietary): fecal microbiota spores, live-brpk
Active ingredients: Donor human stool spores (Ethanol treated) — 30000000 [CFU]/1
Dosage form: Capsule
Route: Oral
Labeler: Aimmune Therapeutics, Inc.
Product type: Prescription drug
Marketing category: BLA — Biologics License ApplicationApplication BLA 125757
Marketing start: Apr 26, 2023
Listing expires: Dec 31, 2027
Identifiers: Product ID 71881-400_cd143fac-e440-417f-bb29-f21b3f8526e5SPL ID cd143fac-e440-417f-bb29-f21b3f8526e5SPL set ID 99e5a37a-930c-4641-bcdd-7013ec1c15feRxCUI 2636542, 2636548UNII 9K7X6R5BMW

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N471881040012 followed by a unit qualifier and the quantity

Package 71881-0400-12. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Apr 23, 2026.

Indications (excerpt from the label)

VOWST is indicated to prevent the recurrence of Clostridioides difficile infection (CDI) in individuals 18 years of age and older following antibacterial treatment for recurrent CDI (rCDI). VOWST is indicated to prevent the recurrence of Clostridioides difficile infection (CDI) in individuals 18 years of age and older following antibacterial treatment for recurrent CDI (rCDI). ( 1 ) Limitation of Use: VOWST is not indicated for treatment of CDI. Limitation of Use: VOWST is not indicated for treatment of CDI.

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)